CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 960 enrolled
Drug / intervention
erlotinib +3 moredrug
Likely dose
erlotinib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00457392
NCT00457392Phase 3Completed
CompareCT.gov

A Multicenter, Randomized, Double-Blind, Controlled Phase 3, Efficacy And Safety Study Of Sunitinib (SU011248) In Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Treated With Erlotinib

Pfizer·interventional·Posted Apr 6, 2007·Updated Oct 29, 2013

In Brief

A Phase 3 clinical trial evaluating erlotinib, sunitinib, and 1 other intervention for Carcinoma, Non-Small Cell Lung. Completed, enrolled 960 participants across 204 sites in 26 countries.

Detailed Summary

This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small Cell Lung
CountriesArgentina, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, Germany, Greece, Hong Kong, Hungary, Italy, Netherlands, Norway, Poland, Russia, Slovakia, South Korea, Spain, Switzerland, Taiwan, Thailand, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 6, 2007
Enrollment StartJul 1, 2007
Primary CompletionJul 1, 2010
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 19.2 years ago

Interventions

erlotinibdrug

plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity

sunitinibdrug

Sunitinib 37.5 mg daily by oral capsules in a continuous regimen

erlotinibdrug

plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity

placebodrug

Placebo daily by oral capsules in a continuous regimen